Učitavanje...
New frontiers in the medical management of gastrointestinal stromal tumours
The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardina...
Spremljeno u:
| Izdano u: | Ther Adv Med Oncol |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535752/ https://ncbi.nlm.nih.gov/pubmed/31205499 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919841946 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|